Skip to content

US · UNCY · BIOTECHNOLOGY

Unicycive Therapeutics, Inc. (UNCY) intrinsic value and stock valuation

$3.35as of 2026-11-21 · Mkt cap 139.64M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Unicycive Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values UNCY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from UNCY’s statements →

Unicycive Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Mountain View, CA 94040 unicycive.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-26.55M
20182025
Free cash flow
-$-31.34M
20182025
Total equity
$30.2M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$680K$950K$0.00
Operating income-$-29.52M-$-32.12M-$-20.77M-$-18.05M-$-8.98M
Net income-$-26.55M-$-36.73M-$-30.54M-$-18.06M-$-10.02M
EPSd-$-167.12K-$-5.48M-$-12.47M-$-11.96M-$-8.56M
Operating cash flow-$-31.32M-$-28.57M-$-18.28M-$-15.65M-$-5.77M
Capital expenditure-$-20K-$-70K-$-10K-$0.00-$-30K
Free cash flow-$-31.34M-$-28.65M-$-18.3M-$-15.65M-$-5.8M
Total assets$49.1M$31.7M$14.2M$2.82M$18.7M
Total debt$200K$770K$810K$200K$340K
Net debt-$-29M-$-25.37M-$-8.89M-$-250K-$-16.24M
Total equity$30.2M$7.43M-$-3.81M-$-470K$16.5M
Cash and short-term investments$41.3M$26.1M$9.7M$460K$16.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$680K$950K$0.00
Cost of revenue$570K$0.00$0.00$0.00$0.00
Gross profit-$-570K$0.00$680K$950K$0.00
Research and development expenses$9.12M$20M$12.9M$12.4M$6.08M
Selling, general and administrative expenses$20.4M$12.1M$8.55M$6.57M$2.9M
Other expenses-$-570K$0.00$0.00$0.00$0.00
Operating expenses$29M$32.1M$21.5M$19M$8.98M
Cost and expenses$29.5M$32.1M$21.5M$19M$8.98M
Interest income$1.01M$1.26M$610K$0.00$0.00
Interest expense$70K$70K$80K$10K$630K
Depreciation and amortization$570K$430K$280K$160K$10K
Ebitda-$-25.91M-$-36.23M-$-30.18M-$-17.89M-$-9.38M
Operating income-$-29.52M-$-32.12M-$-20.77M-$-18.05M-$-8.98M
Total other income/expenses, net$2.96M-$-4.61M-$-9.77M-$-10K-$-1.04M
Income before tax-$-26.55M-$-36.73M-$-30.54M-$-18.06M-$-10.02M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.55M-$-36.73M-$-30.54M-$-18.06M-$-10.02M
Weighted average shares outstanding$158.9M$6.7M$2.45M$1.51M$1.17M
Weighted average diluted shares outstanding$158.9M$6.7M$2.45M$1.51M$1.17M
Balance sheet
20252024202320222021
Cash and short-term investments$41.3M$26.1M$9.7M$460K$16.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$49M$31M$13.4M$2.64M$18.4M
Property, plant and equipment, net$170K$720K$790K$170K$330K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$170K$720K$790K$170K$330K
Total assets$49.1M$31.7M$14.2M$2.82M$18.7M
Accounts payable$300K$970K$820K$850K$740K
Short-term debt$200K$660K$340K$200K$180K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18.9M$24.1M$17.5M$3.28M$2.1M
Long-term debt$0.00$120K$470K$0.00$150K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$120K$470K$0.00$150K
Capital lease obligations$120K$680K$790K$150K$310K
Total liabilities$18.9M$24.2M$18M$3.28M$2.26M
Common stock$20K$110K$40K$10K$10K
Retained earnings-$-127.83M-$-101.27M-$-64.54M-$-34M-$-15.94M
Accumulated other comprehensive income (loss)-$0.00$0.00$0.00$0.00$0.00
Total equity$30.2M$7.43M-$-3.81M-$-470K$16.5M
Total investments$12.1M$0.00$0.00$0.00$0.00
Total debt$200K$770K$810K$200K$340K
Net debt-$-29M-$-25.37M-$-8.89M-$-250K-$-16.24M
Cash flow statement
20252024202320222021
Net income-$-26.55M-$-36.73M-$-30.54M-$-18.06M-$-10.02M
Depreciation and amortization$570K$430K$280K$160K$10K
Stock-based compensation$2.64M$2.35M$1.77M$1.05M$970K
Change in working capital-$-5.95M-$-430K-$-90K$1.18M-$-100K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.5M$790K$1.28M$1.27M$1.24M
Net cash provided by operating activities-$-31.32M-$-28.57M-$-18.28M-$-15.65M-$-5.77M
Investments in property, plant and equipment-$-20K-$-70K-$-10K-$0.00-$-30K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-12.1M-$-70K-$-10K-$0.00-$-30K
Common stock issued$48.1M$680K$0.00$10K$22.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-1.09M$0.00$0.00$0.00
Net cash used for financing activities$46.5M$45.1M$27.5M-$-470K$22.4M
Net change in cash$3.06M$16.4M$9.25M-$-16.12M$16.6M
Cash at end of period$29.2M$26.1M$9.7M$460K$16.6M
Operating cash flow-$-31.32M-$-28.57M-$-18.28M-$-15.65M-$-5.77M
Capital expenditure-$-20K-$-70K-$-10K-$0.00-$-30K
Free cash flow-$-31.34M-$-28.65M-$-18.3M-$-15.65M-$-5.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Unicycive Therapeutics, Inc.

        Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

        CEO
        Shalabh K. Gupta
        Employees
        21
        Beta
        1.79

        Explore

        Frequently asked questions

        What is the intrinsic value of Unicycive Therapeutics, Inc. (UNCY)?

        InvestorsCraft does not currently publish an intrinsic value for UNCY. How the IC value is calculated.

        Is UNCY undervalued?

        InvestorsCraft does not publish an undervaluation signal for UNCY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.